Teva’s Planned Mystery Generic Is Likely Lipitor, Bernstein Says

Teva Pharmaceutical Industries Ltd. (TEVA) may start selling a generic version of Pfizer Inc. (PFE)’s Lipitor this quarter, Sanford C. Bernstein & Co. analysts said in an interpretation of the company’s comments about a large drug it failed to introduce earlier in the year.

“This is ostensibly Lipitor,” analysts led by Ronny Gal wrote in the report late yesterday. “What other product can give Teva 10 cents of earnings per share or $89 million net income in one month?”

Shir Altay, a spokeswoman for the Petach Tikva, Israel- based drugmaker, didn’t respond to telephone and e-mail requests for comment today. Teva said yesterday that if it manages to introduce the “important undisclosed product” in the fourth quarter, it would meet the upper range of its forecast of earnings excluding some costs of $4.92 to $5.02 a share this year.

Lipitor, the biggest product for New York-based Pfizer, is an anti-cholesterol pill.

To contact the reporter on this story: Naomi Kresge in Berlin at nkresge@bloomberg.net

To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.